Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
Last trade$1.72
Day change-$0.21 (-10.88%)
Day range$1.71 – $1.97
Volume139,707
Market cap$24M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for IXHL.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for IXHL.
Recent news
Company coverage with links to the original publishers.
The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.
Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.
Incannex Healthcare announced first patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral fixed-dose combination candidate for treating obstructive sleep apnea. The milestone follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The DReAMzz study aims to optimize dose selection and strengthen the clinical foundation for planned Phase 3 development.
Incannex Healthcare received A$6.0 million in R&D tax incentive refunds from the Australian Government with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million in non-dilutive capital. The company plans to use these proceeds to advance clinical programs including IHL-42X and PSX-001, while maintaining its share repurchase program and strengthening its debt-free balance sheet.
Incannex Healthcare Inc. (Nasdaq: IXHL) has been recognized as the winner of the 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards for its lead drug candidate IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea. The Phase 2 RePOSA trial demonstrated statistically significant improvements in key endpoints including reductions in apnea-hypopnea index, improved oxygenation, sleep quality, and daytime fatigue.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.